Guardant Health (GH) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Guardant Health (GH) overview

Guardant Health (GH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 982m and operating profit of USD -437m; the year-end share price was 102.14 USD and market capitalisation was USD 13,343m. Guardant Health is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Guardant Health's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -99.3mFY 2025
Share price102.14 USDFY 2025 year end
RevenueUSD 982mFY 2025
Operating profitUSD -437mFY 2025
Net earningsUSD -416mFY 2025
Market capitalisationUSD 13,343mFY 2025 year end

About Guardant Health

Guardant Health develops blood and tissue tests, real-world data, and analytics for cancer screening, recurrence monitoring, and treatment selection. Its products include Guardant360 tests for advanced cancers, Guardant Reveal for residual disease and therapy response monitoring, and Shield for colorectal cancer screening. It also provides testing and research analytics to biopharmaceutical companies developing cancer therapies.

Generate the Guardant Health report

Guardant Health is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Guardant Health and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Guardant Health

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.